Tango plans 2027 Phase 3 pancreatic cancer trial, reporting $977.5m in cash

Tango Therapeutics has set out a pivotal-stage plan for its pancreatic cancer programme, saying it expects to begin a Phase 3 study in the first half of 2027. The trial will test vopimetostat together with daraxonrasib in patients who have not yet been treated for pancreatic cancer and whose tumours carry an MTAP deletion. The company disclosed the plan on 9 November 2026 alongside its third-quarter results.

Tango tied the decision to talks with the US Food and Drug Administration and to data shown at the ESMO congress. In patients treated in the second and third line, tumours responded in 82% of cases. The information available does not give patient numbers, response durability or safety detail, so the strength of that result cannot be assessed here.

The company also said it intends to ask regulators whether accelerated approval could be possible in second-line disease. Nothing in the material suggests an agreement has been reached. Context: accelerated approval is a US route that allows earlier authorisation on the strength of surrogate or intermediate endpoints, typically with confirmatory trials required afterwards.

On the balance sheet, Tango reported cash of $977.5m at 30 September 2026. The company did not say in the available information how much of that would go towards the Phase 3 programme, and it gave no pricing, reimbursement or partnering details.